Dermatology providers say chronic hand eczema is widely misunderstood and inadequately managed

Washington DC, March 5, 2025— A LEO Pharma Inc. survey conducted by Ipsos reveals surveyed dermatology providers believe there is a lack of awareness and understanding of chronic hand eczema as a condition separate from eczema, also known as atopic dermatitis.

About the Study

A LEO Pharma Inc. survey conducted by Ipsos fielded an online, 15-minute, self-administered, cross-sectional survey among HCPs currently practicing in the United States during the period between January 10 and February 4, 2025. Respondents were recruited from opt-in panels of HCPs across the country. In order, to participate in the survey, all respondents had to be practicing Dermatologists or a Nurse Practitioner / Physician Assistant (NP/PAs) in a dermatology office and managed at least 10 patients in the past six months with moderate to severe atopic dermatitis on the wrists / hands.

Potential respondents were excluded from participation if they were unwilling to provide informed consent to participate in the study, have an employer-imposed restriction that would prevent participation, were located in Vermont or Michigan (due to transparency reporting laws in these states for HCPs), did not regularly treat patients with atopic dermatitis / eczema, or were unaware of any prescription treatments for moderate-to-severe chronic/reoccurring hand eczema.

The final sample size of 192 HCPs consisted of 100 Dermatologists and 92 (NP/PAs) practicing in a dermatology office. Survey responses weighted according to regional representation. Findings reflect the opinion of these respondents only.

About Ipsos

Ipsos is one of the largest market research and polling companies globally, operating in 90 markets and employing over 18,000 people.

Our passionately curious research professionals, analysts and scientists have built unique multi-specialist capabilities that provide true understanding and powerful insights into the actions, opinions and motivations of citizens, consumers, patients, customers or employees. Our 75 solutions are based on primary data from our surveys, social media monitoring, and qualitative or observational techniques.

Our tagline "Game Changers" sums up our ambition to help our 5,000 customers move confidently through a rapidly changing world.

Founded in France in 1975, Ipsos has been listed on the Euronext Paris since July 1, 1999. The company is part of the SBF 120 and Mid-60 indices and is eligible for the Deferred Settlement Service (SRD).ISIN code FR0000073298, Reuters ISOS.PA, Bloomberg IPS:FP www.ipsos.com